Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
200 shown of 8,304 total abstracts
  1. Abstract LBA4000LBA2026-04-03 · 21:45 CT · E450
    MONALEESA-890: Kisqali (ribociclib) 1L in HR+ breast cancer
    H. Borghaei, M. Reck, N. Rizvi, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 15202026-04-01 · 21:45 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-318
    J. Brahmer, L. Paz-Ares · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract TPS80022026-04-04 · 21:30 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    H. Rugo, C. Saura, M. Reck · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 44382026-04-05 · 20:00 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with biliary tract
    C. Saura, R. Herbst · Massachusetts General Hospital
    Education SessionGastrointestinal Cancer📄🖼️
  5. Abstract 14642026-04-04 · 19:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-29
    P. Schmid, T. Mok, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract TPS80052026-04-01 · 20:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-824
    J. Cortes, M. Krop, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 95692026-04-05 · 13:45 CT · E450
    Quality of life outcomes with Opdivo in patients with NSCLC
    C. Saura, S. Modi, S. Antonia, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 100792026-04-04 · 13:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-521 study)
    M.C. Garassino, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  9. Abstract 16792026-04-05 · 19:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-860
    G. Curigliano, J. Brahmer, S. Modi, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 14002026-04-02 · 19:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-818
    J. Cortes, S. Tolaney, H. Borghaei, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 101172026-04-03 · 13:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Rugo, P. Schmid, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  12. Abstract 91492026-04-03 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-619 study)
    S. Peters, C. Robert · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 90602026-04-03 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    T. Mok, G. Curigliano, S. Tolaney · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 40602026-04-05 · 16:30 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    S. Tolaney, C. Robert, S. Antonia, et al. · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  15. Abstract 17562026-04-04 · 21:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-948 study)
    M. Krop, C. Saura · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 97652026-04-01 · 21:00 CT · E450
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-993
    R. Herbst, S. Peters, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  17. Abstract 11092026-04-03 · 19:30 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    T. Mok, S. Modi, J. Brahmer · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 45222026-04-03 · 14:15 CT · Hall B1
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    J. Cortes, S. Modi, H. Rugo, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract 12622026-04-02 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    C. Robert, R. Herbst, H. Borghaei · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 18652026-04-05 · 21:45 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    P. Schmid, G. Curigliano, H. Rugo, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 97982026-04-04 · 16:45 CT · Hall B1
    FLAURA-668: Tagrisso (osimertinib) 3L+ in NSCLC
    M. Reck, S. Antonia, M. Krop, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract TPS80212026-04-04 · 13:15 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    H. Borghaei, T. Mok, A. Spira, et al. · MD Anderson Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 11232026-04-04 · 18:30 CT · S100A
    MONARCH-71: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    T. Mok, C. Saura · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 97932026-04-03 · 14:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    M. Krop, N. Rizvi, C. Saura, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  25. Abstract 12852026-04-05 · 16:15 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-72
    S. Antonia, S. Tolaney, M. Reck · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 48702026-04-03 · 21:30 CT · S406
    ASCENT-310: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    F. Andre, T. Mok, J. Brahmer, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract 69592026-04-05 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-94 study)
    P. Schmid, M. Krop · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 97542026-04-03 · 14:15 CT · E450
    DESTINY-Breast-598: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    H. Rugo, S. Tolaney · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 13492026-04-01 · 16:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-549 study)
    A. Spira, N. Rizvi, C. Robert · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 15982026-04-05 · 21:00 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    M. Reck, G. Curigliano, N. Rizvi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract TPS80302026-04-04 · 18:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M.C. Garassino, S. Antonia, C. Robert, et al. · Massachusetts General Hospital
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 18102026-04-02 · 21:00 CT · S406
    MONARCH-380: Verzenio (abemaciclib) 2L in HR+ breast cancer
    S. Tolaney, S. Modi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 44572026-04-03 · 14:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-460
    N. Rizvi, J. Brahmer, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 95262026-04-01 · 16:30 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    C. Saura, S. Tolaney, M. Krop · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 99812026-04-03 · 14:45 CT · Arie Crown Theater
    CheckMate-704: Opdivo (nivolumab) 2L in metastatic melanoma
    H. Borghaei, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  36. Abstract 17962026-04-02 · 21:45 CT · S406
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-354
    J. Cortes, R. Herbst, N. Rizvi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 43652026-04-03 · 15:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-147
    S. Modi, E. Winer, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster SessionGastrointestinal Cancer📄🖼️
  38. Abstract 12932026-04-05 · 18:45 CT · E450
    DESTINY-Breast-689: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    G. Curigliano, C. Saura, S. Antonia, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 93882026-04-01 · 13:30 CT · S406
    KEYNOTE-22: Keytruda (pembrolizumab) adjuvant in NSCLC
    S. Modi, G. Curigliano, F. Andre, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 47332026-04-02 · 13:45 CT · E450
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    N. Rizvi, C. Robert, M. Reck · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  41. Abstract 104742026-04-02 · 20:15 CT · E450
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    S. Modi, C. Saura, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  42. Abstract TPS80412026-04-02 · 14:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-997
    M. Krop, A. Spira, F. Andre, et al. · Cleveland Clinic
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  43. Abstract 15272026-04-04 · 16:30 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-77
    S. Peters, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 90902026-04-03 · 16:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-206 study)
    E. Winer, T. Mok, S. Modi · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  45. Abstract 93542026-04-02 · 16:15 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-769 study)
    S. Modi, S. Peters, A. Spira · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  46. Abstract 56722026-04-04 · 15:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in prostate
    M. Krop, C. Saura · University of Chicago
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  47. Abstract 96012026-04-04 · 16:45 CT · S100A
    KEYNOTE-418: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    M. Reck, R. Herbst, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  48. Abstract 18702026-04-03 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-946 study)
    E. Winer, H. Borghaei, S. Tolaney, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 90882026-04-05 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-597
    G. Curigliano, C. Saura, C. Robert, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 56332026-04-03 · 14:00 CT · Arie Crown Theater
    OlympiA-418: Lynparza (olaparib) neoadjuvant in ovarian
    C. Robert, S. Peters, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGynecologic Cancer📄🖼️
  51. Abstract LBA4050LBA2026-04-03 · 19:45 CT · Hall B1
    PALOMA-648: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    E. Winer, S. Peters, M.C. Garassino, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 41812026-04-04 · 19:45 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-925
    H. Borghaei, M.C. Garassino, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 97152026-04-04 · 13:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-385
    L. Paz-Ares, H. Borghaei, M. Reck · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract 16302026-04-04 · 19:15 CT · S406
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-5
    H. Rugo, P. Schmid, A. Spira, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 13732026-04-02 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-152 study)
    P. Schmid, G. Curigliano, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 47462026-04-02 · 20:45 CT · Hall B1
    Long-term follow-up of Enhertu 1L for gastric: DESTINY-Breast-282
    J. Cortes, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  57. Abstract LBA4056LBA2026-04-04 · 18:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with NSCLC
    E. Winer, M. Reck, M. Krop, et al. · Institut Gustave Roussy
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 19072026-04-05 · 19:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-288
    M. Reck, C. Robert, S. Modi · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 10442026-04-03 · 16:15 CT · Arie Crown Theater
    MONARCH-773: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    F. Andre, T. Mok, R. Herbst, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 16932026-04-04 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-426 study)
    H. Rugo, M. Reck, S. Peters, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 11462026-04-03 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    F. Andre, S. Modi, S. Antonia · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 102062026-04-03 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    E. Winer, M. Krop, S. Peters · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  63. Abstract 90322026-04-05 · 16:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-59
    M.C. Garassino, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract LBA4063LBA2026-04-01 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-188
    H. Rugo, E. Winer, M. Reck, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 16052026-04-04 · 21:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-860
    C. Saura, F. Andre, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract LBA4065LBA2026-04-05 · 14:00 CT · S406
    OlympiA-552: Lynparza (olaparib) 2L in ovarian
    S. Antonia, S. Peters · Mayo Clinic
    Late-Breaking Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  67. Abstract 15292026-04-04 · 18:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-109
    S. Modi, H. Rugo, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 49392026-04-05 · 16:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-477
    J. Brahmer, S. Antonia, H. Rugo, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 91602026-04-01 · 16:00 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-184
    F. Andre, H. Borghaei, L. Paz-Ares, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 68142026-04-04 · 14:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    R. Herbst, A. Spira, S. Modi, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  71. Abstract 92372026-04-04 · 18:15 CT · S406
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-183
    G. Curigliano, A. Spira, M. Krop, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  72. Abstract 63712026-04-02 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-184 study)
    J. Cortes, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  73. Abstract 17942026-04-03 · 13:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-77
    M. Reck, L. Paz-Ares, A. Spira · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 98962026-04-02 · 13:45 CT · S406
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Peters, M.C. Garassino, L. Paz-Ares, et al. · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  75. Abstract LBA4074LBA2026-04-03 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-660 study)
    L. Paz-Ares, C. Saura, C. Robert, et al. · Karolinska Institute
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 46152026-04-04 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-417 study)
    S. Peters, M. Krop · Massachusetts General Hospital
    Poster SessionGastrointestinal Cancer📄🖼️
  77. Abstract 52152026-04-04 · 20:00 CT · S406
    Long-term follow-up of Lynparza maintenance for prostate: OlympiA-267
    M. Krop, A. Spira, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  78. Abstract TPS80772026-04-04 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza neoadjuvant for prostate: OlympiA-124
    F. Andre, A. Spira, C. Saura, et al. · Peter MacCallum Cancer Centre
    Trials in Progress Poster SessionGenitourinary Cancer—Prostate📄🖼️
  79. Abstract 41462026-04-03 · 18:15 CT · S406
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-594
    S. Modi, S. Antonia, H. Borghaei, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract 11242026-04-03 · 20:00 CT · S406
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-483
    C. Saura, M. Krop · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 96732026-04-02 · 13:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-715 study)
    P. Schmid, M. Reck, T. Mok, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  82. Abstract TPS80812026-04-05 · 15:00 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-392
    C. Saura, E. Winer · Mayo Clinic
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 12582026-04-05 · 15:45 CT · S100A
    DESTINY-Breast-665: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    S. Tolaney, M. Krop · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 98662026-04-05 · 16:00 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    M.C. Garassino, H. Borghaei, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  85. Abstract 93042026-04-01 · 18:15 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-757
    J. Cortes, M. Reck, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 93852026-04-05 · 21:00 CT · E450
    DESTINY-Breast-266: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    H. Rugo, M. Reck, C. Robert, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 98502026-04-03 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-701
    L. Paz-Ares, M. Reck, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumMelanoma📄🖼️
  88. Abstract 48582026-04-01 · 15:30 CT · E450
    EV-239: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    R. Herbst, M.C. Garassino · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  89. Abstract 17262026-04-05 · 16:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-48
    C. Robert, S. Tolaney, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract LBA4089LBA2026-04-04 · 15:00 CT · E450
    DESTINY-Breast-513: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    T. Mok, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  91. Abstract LBA4090LBA2026-04-01 · 16:45 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    R. Herbst, C. Saura, F. Andre, et al. · Peter MacCallum Cancer Centre
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  92. Abstract 40292026-04-03 · 18:15 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in HCC
    S. Antonia, R. Herbst, C. Robert, et al. · Stanford Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  93. Abstract 13502026-04-04 · 16:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-470
    C. Saura, S. Antonia · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 19842026-04-01 · 19:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-877
    A. Spira, E. Winer, S. Tolaney, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 93312026-04-02 · 18:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-465
    N. Rizvi, E. Winer, S. Antonia · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 94612026-04-02 · 15:30 CT · Arie Crown Theater
    IMpower-208: Tecentriq (atezolizumab) 3L+ in NSCLC
    C. Saura, L. Paz-Ares, J. Brahmer, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 19022026-04-02 · 18:45 CT · Hall B1
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-757
    T. Mok, C. Robert, J. Cortes, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract LBA4097LBA2026-04-02 · 19:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-221 study)
    J. Cortes, C. Saura, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 98612026-04-01 · 19:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-404 study)
    N. Rizvi, S. Modi, R. Herbst, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 11172026-04-01 · 16:30 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    M. Reck, H. Borghaei, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 49142026-04-02 · 21:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with HCC
    M.C. Garassino, P. Schmid, T. Mok, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  102. Abstract 91482026-04-01 · 14:15 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    N. Rizvi, S. Modi, M. Reck · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 96852026-04-01 · 15:00 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    E. Winer, S. Peters, H. Borghaei · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract e121032026-04-05 · 21:00 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-912
    S. Peters, E. Winer, J. Cortes, et al. · Mayo Clinic
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  105. Abstract 92232026-04-02 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-275 study)
    M. Reck, T. Mok · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 96152026-04-04 · 19:15 CT · S100A
    CheckMate-168: Opdivo (nivolumab) 2L in metastatic melanoma
    A. Spira, H. Borghaei, J. Brahmer · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  107. Abstract 16962026-04-01 · 20:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-357 study)
    M.C. Garassino, T. Mok, C. Robert · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 48572026-04-04 · 21:45 CT · E450
    PACIFIC-286: Imfinzi (durvalumab) 3L+ in biliary tract
    G. Curigliano, J. Cortes, R. Herbst, et al. · Stanford Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  109. Abstract 69782026-04-02 · 20:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-843
    M. Reck, P. Schmid, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  110. Abstract 17832026-04-04 · 13:30 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-81
    C. Robert, N. Rizvi · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract e121102026-04-04 · 19:30 CT · Arie Crown Theater
    FLAURA-415: Tagrisso (osimertinib) 1L in NSCLC
    C. Saura, J. Cortes, S. Peters · Johns Hopkins Kimmel Cancer Center
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 10042026-04-01 · 15:45 CT · Hall B1
    PALOMA-688: Ibrance (palbociclib) 1L in HR+ breast cancer
    R. Herbst, H. Borghaei, S. Modi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 92682026-04-02 · 20:30 CT · E450
    KEYNOTE-329: Keytruda (pembrolizumab) 3L+ in SCLC
    M. Reck, E. Winer, S. Peters, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  114. Abstract LBA4113LBA2026-04-02 · 19:45 CT · S406
    DESTINY-Breast-205: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    S. Tolaney, M. Krop, C. Saura · University of Chicago
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract TPS81142026-04-02 · 15:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-70 study)
    M. Krop, S. Tolaney, J. Cortes, et al. · Massachusetts General Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 15122026-04-03 · 18:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-605 study)
    S. Antonia, S. Peters, R. Herbst · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract e121162026-04-05 · 19:00 CT · Hall B1
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-810
    G. Curigliano, H. Borghaei · Princess Margaret Cancer Centre
    Publication OnlyLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 13042026-04-02 · 21:15 CT · E450
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-85
    H. Borghaei, C. Robert, A. Spira, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract LBA4118LBA2026-04-03 · 20:15 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-768 study)
    H. Rugo, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  120. Abstract 41832026-04-05 · 16:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-665
    G. Curigliano, S. Peters, A. Spira, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  121. Abstract 47522026-04-04 · 15:15 CT · E450
    Long-term follow-up of Tecentriq adjuvant for HCC: IMpower-641
    P. Schmid, C. Robert · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  122. Abstract 11872026-04-01 · 18:15 CT · Arie Crown Theater
    OlympiA-75: Lynparza (olaparib) 2L in HR+ breast cancer
    S. Tolaney, G. Curigliano, H. Borghaei, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 12332026-04-05 · 14:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-124
    C. Robert, R. Herbst, A. Spira, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  124. Abstract 94272026-04-02 · 21:00 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-332
    F. Andre, C. Robert, J. Cortes, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 48342026-04-03 · 19:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-918
    S. Antonia, J. Cortes, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  126. Abstract 17182026-04-04 · 16:00 CT · S406
    MONARCH-56: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    N. Rizvi, H. Borghaei, A. Spira, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 41132026-04-03 · 14:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-280
    J. Cortes, E. Winer, M.C. Garassino · Dana-Farber Cancer Institute
    Poster SessionGastrointestinal Cancer📄🖼️
  128. Abstract 97182026-04-02 · 14:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-225 study)
    L. Paz-Ares, S. Modi, G. Curigliano, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  129. Abstract 18352026-04-05 · 19:00 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-550
    J. Brahmer, M. Reck, H. Rugo, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 41322026-04-04 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-792 study)
    S. Tolaney, M. Krop, S. Peters, et al. · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  131. Abstract 41922026-04-02 · 13:00 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-590
    M. Krop, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  132. Abstract 46122026-04-01 · 20:15 CT · S100A
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-446
    M.C. Garassino, N. Rizvi, F. Andre · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  133. Abstract 18712026-04-02 · 21:00 CT · S406
    Long-term follow-up of Keytruda maintenance for TNBC: KEYNOTE-761
    S. Modi, M.C. Garassino, N. Rizvi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract LBA4133LBA2026-04-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-38 study)
    P. Schmid, M.C. Garassino, M. Krop, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 40022026-04-02 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-687 study)
    N. Rizvi, S. Peters, E. Winer · University of Chicago
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  136. Abstract 93582026-04-01 · 16:30 CT · Arie Crown Theater
    FLAURA-188: Tagrisso (osimertinib) maintenance in NSCLC
    E. Winer, J. Cortes, G. Curigliano, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  137. Abstract 10382026-04-03 · 21:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-452
    C. Robert, G. Curigliano · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 93052026-04-03 · 16:45 CT · S100A
    KEYNOTE-503: Keytruda (pembrolizumab) maintenance in NSCLC
    S. Modi, T. Mok, M. Krop · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 50082026-04-04 · 14:45 CT · Arie Crown Theater
    OlympiA-989: Lynparza (olaparib) adjuvant in prostate
    A. Spira, H. Rugo, P. Schmid, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Prostate📄🖼️
  140. Abstract 53082026-04-04 · 13:00 CT · S100A
    Long-term follow-up of Lynparza adjuvant for prostate: OlympiA-951
    S. Modi, S. Peters, P. Schmid · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  141. Abstract TPS81402026-04-03 · 21:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-947
    M.C. Garassino, S. Peters, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Trials in Progress Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract 90682026-04-04 · 21:00 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-898
    S. Modi, J. Brahmer · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  143. Abstract LBA4142LBA2026-04-03 · 14:30 CT · S100A
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-847
    S. Modi, M.C. Garassino, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 40702026-04-04 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu adjuvant for gastric: DESTINY-Breast-765
    M.C. Garassino, A. Spira · Peter MacCallum Cancer Centre
    Poster SessionGastrointestinal Cancer📄🖼️
  145. Abstract 14662026-04-05 · 21:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-90
    P. Schmid, S. Tolaney, N. Rizvi, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 43672026-04-04 · 15:00 CT · S406
    ASCENT-779: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    S. Antonia, J. Cortes, T. Mok, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  147. Abstract 98792026-04-02 · 16:45 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-32
    A. Spira, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  148. Abstract 98792026-04-03 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-392 study)
    A. Spira, S. Modi, T. Mok, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  149. Abstract 14052026-04-04 · 16:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-97 study)
    M. Krop, C. Robert, N. Rizvi · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 12562026-04-01 · 18:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-459
    F. Andre, L. Paz-Ares · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 93422026-04-02 · 14:45 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-752
    J. Cortes, S. Antonia, F. Andre · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  152. Abstract 91662026-04-04 · 20:30 CT · S100A
    IMpower-466: Tecentriq (atezolizumab) 2L in NSCLC
    J. Brahmer, H. Borghaei, F. Andre, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  153. Abstract TPS81522026-04-05 · 13:45 CT · S406
    EV-501: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    S. Modi, S. Peters · Massachusetts General Hospital
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  154. Abstract 14972026-04-02 · 13:00 CT · E450
    MONARCH-43: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Rugo, S. Peters, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 19722026-04-04 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-99
    C. Saura, J. Cortes · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 42142026-04-01 · 15:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-707
    F. Andre, C. Saura, C. Robert · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  157. Abstract 19992026-04-02 · 16:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-45 study)
    J. Brahmer, C. Saura, F. Andre · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 41582026-04-02 · 13:45 CT · S100A
    PACIFIC-234: Imfinzi (durvalumab) 3L+ in biliary tract
    C. Saura, J. Cortes, S. Modi, et al. · Cleveland Clinic
    Poster SessionGastrointestinal Cancer📄🖼️
  159. Abstract 65832026-04-02 · 14:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-22
    C. Robert, E. Winer, P. Schmid, et al. · Stanford Cancer Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  160. Abstract 19342026-04-04 · 21:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-279
    A. Spira, M. Reck, S. Antonia, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 92542026-04-01 · 20:30 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-317
    A. Spira, T. Mok, N. Rizvi · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  162. Abstract LBA4161LBA2026-04-01 · 19:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-613 study)
    S. Tolaney, M. Krop · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract LBA4162LBA2026-04-01 · 13:30 CT · Arie Crown Theater
    DESTINY-Breast-548: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    S. Peters, L. Paz-Ares, H. Borghaei, et al. · Karolinska Institute
    Late-Breaking Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  164. Abstract 91412026-04-02 · 15:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-4
    A. Spira, M.C. Garassino, N. Rizvi · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  165. Abstract 46162026-04-01 · 15:30 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    L. Paz-Ares, J. Brahmer, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  166. Abstract 19002026-04-05 · 19:15 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-506
    J. Brahmer, M. Krop · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  167. Abstract 48512026-04-05 · 14:45 CT · Hall B1
    Long-term follow-up of Tecentriq 3L+ for HCC: IMpower-170
    G. Curigliano, F. Andre, P. Schmid · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  168. Abstract 95152026-04-04 · 16:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-210 study)
    L. Paz-Ares, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 68662026-04-05 · 18:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-713
    S. Modi, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  170. Abstract 11272026-04-01 · 18:30 CT · S100A
    ASCENT-413: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    G. Curigliano, C. Robert, R. Herbst · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract LBA4170LBA2026-04-01 · 14:00 CT · E450
    Long-term follow-up of Enhertu 2L for gastric: DESTINY-Breast-182
    L. Paz-Ares, S. Antonia, R. Herbst · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  172. Abstract 91602026-04-02 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-149
    A. Spira, E. Winer, M. Krop · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  173. Abstract 15452026-04-04 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-943 study)
    J. Cortes, H. Rugo, M. Krop, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 10862026-04-03 · 13:45 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-349
    S. Tolaney, H. Borghaei, M.C. Garassino, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 96872026-04-05 · 18:15 CT · E450
    Long-term follow-up of Imfinzi adjuvant for SCLC: PACIFIC-106
    A. Spira, S. Tolaney, G. Curigliano · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  176. Abstract 45182026-04-01 · 13:15 CT · S406
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-766
    P. Schmid, J. Brahmer, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionGastrointestinal Cancer📄🖼️
  177. Abstract 48202026-04-04 · 13:00 CT · E450
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-366
    M. Krop, E. Winer, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  178. Abstract 97642026-04-03 · 15:45 CT · S100A
    FLAURA-907: Tagrisso (osimertinib) adjuvant in NSCLC
    R. Herbst, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  179. Abstract 91002026-04-05 · 14:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-114
    S. Tolaney, L. Paz-Ares, A. Spira · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  180. Abstract 10602026-04-05 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-349 study)
    P. Schmid, S. Modi, R. Herbst, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 12772026-04-05 · 14:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-22 study)
    C. Robert, S. Antonia, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 14782026-04-05 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-431 study)
    H. Borghaei, N. Rizvi, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 99282026-04-02 · 14:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-328
    S. Tolaney, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  184. Abstract 92652026-04-05 · 15:00 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-468 study)
    S. Tolaney, M. Reck · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  185. Abstract 17142026-04-05 · 15:00 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-534
    C. Robert, M. Krop, M. Reck, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  186. Abstract TPS81852026-04-01 · 14:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-864
    M. Reck, N. Rizvi, E. Winer · University of Chicago
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 96772026-04-04 · 20:45 CT · E450
    IMpower-634: Tecentriq (atezolizumab) adjuvant in NSCLC
    R. Herbst, N. Rizvi, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 19232026-04-05 · 19:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-505
    H. Rugo, S. Tolaney, S. Modi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 14832026-04-05 · 16:00 CT · S406
    KEYNOTE-240: Keytruda (pembrolizumab) neoadjuvant in TNBC
    F. Andre, C. Saura, C. Robert · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 18362026-04-03 · 20:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-844
    G. Curigliano, J. Cortes, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  191. Abstract 46302026-04-01 · 15:45 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    C. Saura, P. Schmid, M. Reck, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  192. Abstract 11832026-04-05 · 13:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-902 study)
    G. Curigliano, N. Rizvi · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 11902026-04-01 · 13:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-925
    E. Winer, A. Spira, C. Robert, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 12222026-04-03 · 16:45 CT · Arie Crown Theater
    IMpower-187: Tecentriq (atezolizumab) neoadjuvant in TNBC
    H. Borghaei, L. Paz-Ares, S. Antonia · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 98402026-04-03 · 18:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-543 study)
    J. Cortes, L. Paz-Ares, M.C. Garassino · Institut Gustave Roussy
    Oral Abstract SessionMelanoma📄🖼️🎬
  196. Abstract 90372026-04-04 · 19:15 CT · Hall B1
    PACIFIC-702: Imfinzi (durvalumab) 2L in NSCLC
    M.C. Garassino, S. Peters, R. Herbst, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  197. Abstract TPS81962026-04-02 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-250 study)
    R. Herbst, G. Curigliano, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 18252026-04-05 · 14:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    H. Rugo, M. Reck, S. Peters, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 16472026-04-04 · 20:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-562 study)
    P. Schmid, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 12442026-04-05 · 21:30 CT · S100A
    PALOMA-82: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, S. Tolaney, E. Winer · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.